Generalized cost-effectiveness analysis of a package of interventions to reduce cardiovascular disease in Buenos Aires, Argentina

Cost Effectiveness and Resource Allocation

Volumn 7, Issue , 2009, Pages

  Rubinstein, Adolfo ^a,b   García Martí, Sebastián ^a   Souto, Alberto ^a   Ferrante, Daniel ^a   Augustovski, Federico ^a,b  

^a INSTITUTE FOR CLINICAL EFFECTIVENESS AND HEALTH POLICY   (Argentina)

^b HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMFEBUTAMONE; ATENOLOL; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; THIAZIDE DIURETIC AGENT;

ARGENTINA; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; HEALTH CARE COST; HEALTH SERVICE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INCIDENCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL EDUCATION; OBESITY; POPULATION RESEARCH; PREVALENCE; RISK REDUCTION; SMOKING; SMOKING CESSATION; SODIUM RESTRICTION;

EID: 66149170110     PISSN: None     EISSN: 14787547     Source Type: Journal    
DOI: 10.1186/1478-7547-7-10     Document Type: Article

References (37)

1. Mathers CD LA Stein C Fat DM Rao C Deaths and disease burden by cause: global burden of disease estimates for 2001 by World Bank Country Groups. Working paper 18. Bethesda, MD: Disease Control Priorities Project 2005. 15798840
2. Defunciones por causas, Argentina, 2004. Dirección de Estadísticas e Información. Ministerio de Salud de la Nación
3. Lopez AD Mathers CD Ezzati M Jamison DT Murray CJ Global and regional burden of disease and risk factors, 2001: Systematic analysis of population health data Lancet 2006, 367:1747-1757. 10.1016/ S0140-6736(06)68770-9 16731270
4. Primera Encuesta Nacional de Factores de Riesgo. Primera Edición - Buenos Aires. Ministerio de Salud de la Nación 2006.
5. Schargrodsky H Hernandez-Hernandez R Champagne BM Silva H Vinueza R Silva Aycaguer LC Touboul PJ Boissonnet CP Escobedo J Pellegrini F Macchia A Wilson E CARMELA Study Investigators CARMELA: Assessment of cardiovascular risk in seven Latin American cities Am J Med 2008, 121:58-65. 10.1016/j.amjmed.2007.08.038 18187074
6. Preventing chronic diseases: A vital investment WHO global report. Geneva 2005.
7. Strong K Mathers C Leeder S Beaglehole R Preventing chronic diseases: how many lives can we save? Lancet 2005, 366:1578-1582. 10.1016/ S0140-6736(05)67341-2 16257345
8. Abegunde DO Mathers CD Adam T Ortegon M Strong K The burden and costs of chronic diseases in low-income and middle-income countries Lancet 2007, 370:1929-1938. 10.1016/S0140-6736(07)61696-1 18063029
9. Murray CJLLA The Global Burden of Disease: A comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Cambridge MA: Harvard University Press Murray CJL, Lopez AD 1 1996.
10. World Health Organization The World Health Report: Reducing risks, Promoting Healthy Life Geneva: World Health Organization 2002.
11. Rubinstein A Belizan M Discacciati V Are economic evaluations and health technology assessments increasingly demanded in times of rationing health services? The case of the Argentine financial crisis Int J Technol Assess Health Care 2007, 23:169-176. 10.1017/S0266462307070274 17493302
12. Murray CJ Lauer JA Hutubessy RC Niessen L Tomijima N Rodgers A Lawes CM Evans DB Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: A global and regional analysis on reduction of cardiovascular-disease risk Lancet 2003, 361:717-725. 10.1016/S0140-6736(03)12655-4 12620735
13. Gaziano TA Opie LH Weinstein MC Cardiovascular disease prevention with a multidrug regimen in the developing world: A cost-effectiveness analysis Lancet 2006, 368:679-686. 10.1016/S0140-6736(06)69252-0 16920473 2365896
14. World Health Organization Making choices in health: WHO Guide to Cost-Effectiveness Analysys WHO Library Tan-Torres Edejer T, et al 2003.
15. Relevamiento del uso de sal en los productos de panaderías artesanales de la República Argentina e implementación de acciones de desarrollo, tecnológicas, de asistencia técnica y extensión con el objeto de bajar su utilización y consumo. Programa VIGI+A 2005.
16. He FJ MacGregor GA How far should salt intake be reduced? Hypertension 2003, 42:1093-1099. 10.1161/01.HYP.0000102864.05174.E8 14610100
17. Sellers DE Crawford SL Bullock K McKinlay JB Understanding the variability in the effectiveness of community heart health programs: A meta-analysis Soc Sci Med 1997, 44:1325-1339. 10.1016/ S0277-9536(96)00263-8 9141165
18. The Canadian Hypertension Education Program Recommendations 2004.
19. Law MR Wald NJ Rudnicka AR Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: Systematic review and meta-analysis Bmj 2003, 326:1423. 10.1136/bmj.326.7404.1423 12829554 162260
20. Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Adult Treatment Panel III 2002.
21. Hughes J Stead L Lancaster T Antidepressants for smoking cessation Cochrane Database Syst Rev 2004:CD000031. 15494986
22. Encuesta de Tabaquismo en grandes ciudades de Argentina - 2004. Ministerio de Salud y Ambiente de la Nación 2005.
23. Wald NJ Law MR A strategy to reduce cardiovascular disease by more than 80% Bmj 2003, 326:1419. 10.1136/bmj.326.7404.1419 12829553 162259
24. Wilson PW D'Agostino RB Levy D Belanger AM Silbershatz H Kannel WB Prediction of coronary heart disease using risk factor categories Circulation 1998, 97:1837-1847. 9603539
25. Lauer JA Rohrich K Wirth H Charette C Gribble S Murray CJ PopMod: A longitudinal population model with two interacting disease states Cost Eff Resour Alloc 2003, 1:6. 10.1186/1478-7547-1-6 12773215 156025
26. Gimpel N SV Rubinstein A Quality Management of Hypertension in Primary Care: Do physicians treat blood pressure level or patients' risk? Quality in Primary Care 2006, 14:211-217.
27. Jamison D et al. 'Investing in health', in D Jamison et al., Disease Control Priorities in Developing Countries New York: Oxford University Press 2 2006:3-36.
28. Asaria P Chisholm D Mathers C Ezzati M Beaglehole R Chronic disease prevention: Health effects and financial costs of strategies to reduce salt intake and control tobacco use Lancet 2007, 370:2044-2053. 10.1016/ S0140-6736(07)61698-5 18063027
29. Lim SS Gaziano TA Gakidou E Reddy KS Farzadfar F Lozano R Rodgers A Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: Health effects and costs Lancet 2007, 370:2054-2062. 10.1016/S0140-6736(07)61699-7 18063025
30. Batussen RMAT Tan Torres T et al Generalized cost-effectiveness analysis: A guide. Global Programme on Evidence for Health Policy Geneva: WHO 2002.
31. http://siteresources.worldbank.org/DATASTATISTICS/Resources/GNIPC05.pdf
32. Ezzati M Lopez AD Rodgers A Hoorn Vander S Murray CJ Selected major risk factors and global and regional burden of disease Lancet 2002, 360:1347-1360. 10.1016/S0140-6736(02)11403-6 12423980
33. Yusuf S Hawken S Ounpuu S Dans T Avezum A Lanas F McQueen M Budaj A Pais P Varigos J Lisheng L Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study Lancet 2004, 364:937-952. 10.1016/ S0140-6736(04)17018-9 15364185
34. Kannel WB Risk stratification in hypertension: New insights from the Framingham Study Am J Hypertens 2000, 13:3S-10S. 10.1016/ S0895-7061(99)00252-6 10678282
35. Brownson Chronic Disease Epidemiology and Control American Public Health Association 2 1998.
36. Bronner LL Kanter DS Manson JE Primary prevention of stroke N Engl J Med 1995, 333:1392-1400. 10.1056/NEJM199511233332106 7477121
37. Law MR Wald NJ Morris JK Jordan RE Value of low dose combination treatment with blood pressure lowering drugs: Analysis of 354 randomised trials BMJ 2003, 326:1427. 10.1136/bmj.326.7404.1427 12829555 162261